U.S., May 27 -- ClinicalTrials.gov registry received information related to the study (NCT07607561) titled 'Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration' on May 14.
Brief Summary: Trial to Evaluate the Safety and Efficacy of SCAI-005 Ophthalmic solution in Patients with Neovascular Age-related Macular Degeneration.
The purpose of this study is to investigate the efficacy, safety and tolerability of SCAI-005 Ophthalmic solution by dose in patients with neovascular Age-related Macular Degeneration (nAMD).
Study Start Date: Nov. 01, 2026
Study Type: INTERVENTIONAL
Condition:
wetAMD
Age Related Macular Degeneration
Intervention:
DRUG: SCA...